CN101574391B - Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside - Google Patents
Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside Download PDFInfo
- Publication number
- CN101574391B CN101574391B CN200810052995A CN200810052995A CN101574391B CN 101574391 B CN101574391 B CN 101574391B CN 200810052995 A CN200810052995 A CN 200810052995A CN 200810052995 A CN200810052995 A CN 200810052995A CN 101574391 B CN101574391 B CN 101574391B
- Authority
- CN
- China
- Prior art keywords
- salviae miltiorrhizae
- application
- phenolic acids
- radix notoginseng
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000004089 microcirculation Effects 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 10
- 201000010099 disease Diseases 0.000 title abstract description 9
- 230000002265 prevention Effects 0.000 title abstract description 5
- 235000002791 Panax Nutrition 0.000 title abstract 3
- 241000208343 Panax Species 0.000 title abstract 3
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title abstract 3
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 title abstract 3
- 229930183842 salvianolic acid Natural products 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 17
- 241000180649 Panax notoginseng Species 0.000 claims description 61
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 61
- 150000007965 phenolic acids Chemical class 0.000 claims description 52
- 235000009048 phenolic acids Nutrition 0.000 claims description 52
- 210000003630 histaminocyte Anatomy 0.000 claims description 19
- 208000028867 ischemia Diseases 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 210000000713 mesentery Anatomy 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 4
- 206010048768 Dermatosis Diseases 0.000 claims description 4
- 206010048908 Seasonal allergy Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000017520 skin disease Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 210000003462 vein Anatomy 0.000 description 13
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 12
- 210000004204 blood vessel Anatomy 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- -1 phenolic acid compound Chemical class 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000002565 arteriole Anatomy 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100208128 Arabidopsis thaliana TSA1 gene Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 101100201844 Homo sapiens RSPH1 gene Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100035089 Radial spoke head 1 homolog Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 101150104676 TSA2 gene Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000218606 Pinus contorta Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000000673 shore pine Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
Abstract
The invention relates to a new application of the compatibility of a traditional Chinese medicine total salvianolic acid and panax notoginoside, in particular to prevention and treatment of diseases induced by microcirculation disturbance with the compatible combination of total salvianolic acid and panax notoginoside.
Description
Technical field:
The present invention relates to the new purposes of the compatibility of tcm product Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins, particularly the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is to the prevention and treatment of diseases effect of microcirculation disturbance initiation.
Background technology:
Radix Salviae Miltiorrhizae total phenolic acids (TSA) is the general name of phenolic acid compound in the red sage root water soluble ingredient.Radix Salviae Miltiorrhizae total phenolic acids can be applicable to prepare in the medicament of treatment cardiovascular and cerebrovascular disease, nephropathy, hepatopathy, pneumonia, pulmonary heart disease, pancreatitis, diabetes, cervical spondylosis, optical fundus blood vessel property disease, optical fundus nervous system disease, migraine, chronic gastritis, dizzy, Bone injury disease, high altitude disease, senile dementia etc.The method for preparing of Radix Salviae Miltiorrhizae total phenolic acids (TSA) has multiple; Be exemplified below: salvia piece or Radix Salviae Miltiorrhizae coarse powder elder generation's water or diluted alkaline in 30～99 ℃ carry at the beginning of down the water soluble ingredient in the Radix Salviae Miltiorrhizae; Extracting solution adds acid accent pH1～6 then; After deposition was removed impurity, convection drying or concentrated after drying got the extractum powder; Dry gained extractum powder is with 50～90% ethanol water reflux, extract, 1～4 time, and merge extractive liquid, leaves standstill, and gets supernatant, promptly gets high-purity Radix Salviae Miltiorrhizae total phenolic acids solution; Gained solution convection drying or concentrated after drying promptly get described Radix Salviae Miltiorrhizae total phenolic acids extractum powder.
Radix Notoginseng is the root of Araliaceae herbaceos perennial Radix Notoginseng Ranax notoginseng (Burk) F.H.Chen; Main product is in Yunnan, Guangxi and other places; Another name Radix Notoginseng, Radix Notoginseng. the main active of Radix Notoginseng is a Radix Notoginseng total arasaponins; It is about 12% to contain saponin in its tuber, isolates 20 kinds of dammarane type saponin from each position of Radix Notoginseng at present. and particularly the research of cardiovascular and cerebrovascular vessel pharmacology effect is very active to the pharmacological action of Radix Notoginseng total arasaponins both at home and abroad.Radix Notoginseng total arasaponins (PNS) has been listed NF in, and the corresponding preparations launch is arranged, as: panax notoginseng saponins for injection.Chinese patent CN200410058111.4 has described a kind of method for preparing of Radix Notoginseng total arasaponins: Radix Notoginseng is used water extraction, and extracting solution concentrates, ethanol precipitation; Supernatant eliminates ethanol, behind the water dissolution, and row macroporous resin HPD400 column chromatography; After water elution is removed impurity, reuse 90% ethanol elution, to the effective ingredient eluting fully till; Reclaim alcohol eluen, be drying to obtain.Specifically can adopt following method to obtain: to get pseudo-ginseng and be ground into coarse powder, add 70% ethanol of 10 times of medical material weight, reflux, extract, 2 times; Each 25 hours, filter, merge secondary raffinate; 70 ℃ of left and right sides decompression and solvent recoveries are the fluid extract of 1.10-1.12 to proportion.Dilute with water carries out the absorption of macroporous resin HPD400 adsorption column, uses water elution, continues with 90% ethanol elution 70 ℃ of left and right sides decompression and solvent recoveries of 90% ethanol elution part.In above-mentioned Radix Notoginseng total arasaponins solution, add MgO
2: AL
20
3Decolouring is filtered, and filtrates in 80 ℃ of reduced vacuum dryings, pulverizes, and promptly gets faint yellow Radix Notoginseng total arasaponins finished product.
Ischemical reperfusion injury is the main pathological basis that occurs damage behind interventional therapy, surgical operation, the thrombolytic.The main pathology link that leukocyte and vascular endothelial cell stick behind the ischemia-reperfusion, mast cell degranulation is blood vessel injury.
Microcirculation is the vascular bed that comprises arteriole, blood capillary, thin vein, accounts for 90% of the interior blood vessel of body, is to keep metabolic pith.Hyperlipemia, hypertension, infection, direct stimulation, traumatic injury, operation, interventional therapy etc. can cause microcirculation disturbance.Microcirculation disturbance comprises that blood vessel directly changes, peroxide generation, blood vessel endothelium adhesion factor ICAM-1, leukocyte adhesion factor CD11b/CD18 expression, leukocyte and vaso-active substance such as vascular endothelial cell adheres to, plasma albumin leaks outside, the outer mast cell degranulation of blood vessel discharges TNF-α, histamine, five hydroxytryptamine, inflammatory factor and form the complex process that blood is fastened, too many levels such as hemorrhage changes.
Mast cell degranulation is the main pathology link of an allergic reaction type, is pollinosis, dermatosis, asthma, diarrheal main pathological basis.
Whether the compatibility that it be not immediately clear Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins can improve the microcirculation disturbance that ischemia-reperfusion causes.The present invention has proved that the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins can improve the mesentery microcirculation disturbance that ischemia-reperfusion causes, thereby reaches the effect of the disease that treats and/or prevents the microcirculation disturbance initiation, and a kind of Chinese medicine pharmaceutical preparation is provided.
Summary of the invention:
The present invention relates to the new purposes of tcm product, particularly the prevention and the treatment improvement effect of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins mesentery microcirculation disturbance that ischemia-reperfusion is caused.Thereby be applied to treat and/or prevent the disease that microcirculation disturbance causes, as: hyperlipemia, hypertension, infection, direct stimulation, traumatic injury, pollinosis, dermatosis, asthma, the microcirculation disturbance that diarrhoea, operation or interventional therapy etc. cause.
The present invention finds, 8: 2 compatibilities of TSA and PNS and 2: 8 compatibilities of TSA and PNS all can suppress leukocytic adhesion and mast cell degranulation.
Radix Salviae Miltiorrhizae total phenolic acids according to the invention, Radix Notoginseng total arasaponins can have been bought from market, also can meet medicinal standard and get final product according to prior art for preparing.
The medicine of preparation according to the invention is the pharmaceutical composition that the compatibility with above-mentioned Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is prepared into as active constituents of medicine.
Pharmaceutical composition of the present invention comprises the pharmaceutical composition of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins as active component, and Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins are with the weight proportion combination of 1-9: the 1-9 pharmaceutical composition as active component.Preferably Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins are with the weight proportion combination of 2: 8 and 8: 2 pharmaceutical composition as active component.
Pharmaceutical composition of the present invention; Can contain the medicine acceptable carrier as required; Wherein the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is as active constituents of medicine, and its shared percentage by weight in compositions can be 0.1-99.9%, and all the other are the medicine acceptable carrier.Pharmaceutical composition of the present invention exists with unit dosage form, and said unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule, every of injection etc.
Pharmaceutical composition of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.
Pharmaceutical composition of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill through mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive; Such as suspending agent; For example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat; Emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, can this chemical compound be suspended or dissolving.The preparation of solution is normally through being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Pharmaceutical composition of the present invention; When being prepared into medicament, optionally add suitable medicine acceptable carrier; Said medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Pharmaceutical composition of the present invention is confirmed usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet, every dose of 1mg-1000mg.
Therapeutic use of the present invention proves through following experiment:
Material and method
Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins provide by Tianjin Tasly Pharmaceutical Co., Ltd.
Laboratory animal
The Wister male rat of 200～250g is provided by Department Of Medicine, Peking University's animal center, and fasting 12 hours before the test can freely be drunk water, the animal quality certification number: SCXK (capital) 2002-0001.Animal is placed in conventional feeding environment, and the processing of animal handles according to the animal of Department Of Medicine, Peking University's regulation and the ethics policy is carried out.
The foundation of ischemia-reperfusion model and administration:
Ischemia-reperfusion group (I/R): press the consumption of 30mg/kg body weight, get sodium pentobarbital, execute lumbar injection and anaesthetize.Right external jugular vein rat is inserted No. 3 polyethylene intravenous tube, and keeps somewhere.Cut 20-30mm along the abdomen median line, softly nearly the ileum of ileocecus takes out outside the abdomen, is expanded on the observation platform of microscope slide.Krebs-Ringer buffer with 37 ℃ drips on unfolded mesentery continuously.The mesentery microcirculation dynamically with the handstand biological microscope (Diaphot TMD-2S, Nikon, Tokyo) that places 37 ℃ of calorstats, at 12V, is observed under the white light conditions of 100W.Under 20 times of composition lens, select look-out station,, observed content is preserved with the record of S-VHS video-tape with the free video recording system that shows.The look-out station of selecting is the microcirculatory vascular bed of diameter at the non-branch part of the thin vein between the 25-35um (length is more than 200 μ m).After observing through 10 minutes bases,, remove ligation again, will transfer to 0 place the time, observe dynamic 30 minutes of the microcirculation (1) of the same visual field continuously with the preceding mesentery arteriovenous of polyethylene tube ligation observation portion circulation 10 minutes.
Sham operated rats (Sham): rat anesthesia is opened abdomen, do not make ischemia-reperfusion and handle.
8: 2 preparatory administration groups of compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins (Radix Salviae Miltiorrhizae total phenolic acids 8: Radix Notoginseng total arasaponins 2+I/R): ischemia before 20 minutes through jugular vein by the dosage of the 5mg/kg/h quiet Radix Salviae Miltiorrhizae total phenolic acids 8 that splashes into continuously: Radix Notoginseng total arasaponins 2 solution finish to observing.
2: 8 preparatory administration groups of compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins (Radix Salviae Miltiorrhizae total phenolic acids 2: Radix Notoginseng total arasaponins 8+I/R): ischemia before 20 minutes through jugular vein by the dosage of the 5mg/kg/h quiet Radix Salviae Miltiorrhizae total phenolic acids 2 that splashes into continuously: Radix Notoginseng total arasaponins 8 solution finish to observing.
Every group of 6 rats.
Microcirculation is observed dynamically:
Microcirculation is dynamically with CCD camera system (CC-090, Flovel, Tokyo) that is connected in the handstand biological microscope and SIT fluorescent camera (C-2400-08, shore pine Off オ ト ニ Network ス, shore pine) record continuously.
The mensuration of blood vessel warp: survey blood vessel through time ground through (1,2) with video measuring gauge (IV-560, ホ ウ エ イ, Tokyo).
Adhere to the leukocyte count counting of thin vein tube wall: on the image of record, through the time ground counting stop the leukocyte (adhesion leukocyte) more than 30 seconds at the same position of thin vein tube wall, calculate adherent leukocyte count (1,2) on the long thin vein of 200 μ m.
Mast cell degranulation rate:, after 30 minutes 0.1%tolui dine blue is dripped at look-out station at ischemia-reperfusion, note down with ccd video camera.With 20 times to 5 visuals field of object lens countings take off granule and not degranulated mastocyte number, calculate the percentage ratio that degranulated mastocyte accounts for the whole mastocyte number of counting, be mast cell degranulation rate (1,2).
Statistical disposition:
Each measured value is handled with one-way analysis of variance (ANOVA), each group through the time change check with T, relatively check between each group with F.Each measured value representes that with the mean standard error P＜0.05 is a significance.
The result
1, the preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is to the influence of perfusion back rat mesentery arteriole and thin vein blood vessel warp again.
In this observing time, ischemia-reperfusion group rat arteriole and thin vein blood vessel directly do not have to take place significant the variation. and Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins are united preparatory administration (TSA8: PNS2 and TSA2: PNS8) all do not cause the significant change of pouring into back rat mesentery arteriole and thin vein blood vessel footpath again.
2, the preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is to pour into back rat leukocyte and the adherent inhibitory action of mesentery thin vein again.
As shown in Figure 1, the Sham group only has a spot of leukocyte adhesion in thin vein when this observation finishes.I/R group rat just has a large amount of leukocyte adhesions in the thin vein tube wall in early days in perfusion again, along with dabbling carrying out again, sticks leukocyte and increases gradually.The preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins (TSA8: PNS2 and TSA2: PNS8) when perfusion begins again, just suppressed leukocytic adhesion significantly.
3, the preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is to the influence of matter mast cell degranulation between the rat mesentery of perfusion back again.
Fig. 2 shows that Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins unite preparatory administration to the influence of matter mast cell degranulation between the mesentery of perfusion back again.After pouring into 30 fens again, significantly increase with the mast cell degranulation rate of sham operated rats than, I/R group.The preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins (TSA8: PNS2 and TSA2: PNS8) can suppress mast cell degranulation significantly.
Rat intestine cell membrane blood vessel does not directly have significant change behind the ischemia-reperfusion, and the leukocyte count and the mast cell degranulation rate in the blood vessel outer room matter tissue that stick on the thin vein tube wall significantly increase.8: 2 compatibility groups of TSA and PNS and 2: 8 compatibility groups of TSA and PNS all can suppress leukocytic adhesion and mast cell degranulation.
In a word, this research shows, the microcirculation disturbance that ischemia-reperfusion causes can prevented and treat to 8: 2 compatibility groups of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins and 2: 8 compatibility groups of TSA and PNS.Thereby be applied to treat and/or prevent the disease that microcirculation disturbance causes; As: hyperlipemia, hypertension, infection etc. and because of direct stimulation, traumatic injury, pollinosis; Dermatosis, asthma, the microcirculation disturbance that diarrhoea, operation or interventional therapy etc. cause.
Description of drawings:
Fig. 1 representes that the Sham group only has a spot of leukocyte adhesion in thin vein when this observation finishes.
Fig. 2 representes that the preparatory administration of the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is to the influence of matter mast cell degranulation between the mesentery of perfusion back again.
The specific embodiment:
Below further specify the present invention through embodiment, but not as limitation of the present invention.
Embodiment 1
Tablet
[prescription] Radix Notoginseng total arasaponins 90g Radix Salviae Miltiorrhizae total phenolic acids 10g calcium sulfate 150g
Microcrystalline Cellulose 50g micropowder silica gel 3g magnesium stearate 1.5g
[method for making] got former, adjuvant and crossed 100 mesh sieves respectively; Get Radix Notoginseng total arasaponins, Radix Salviae Miltiorrhizae total phenolic acids, calcium sulfate, microcrystalline Cellulose, mixing in right amount as binding agent system soft material, is crossed 20 mesh sieve system granules with 60% ethanol; 60 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add micropowder silica gel and magnesium stearate; Mixing, tabletting is processed 1000, promptly gets.
Embodiment 2
[prescription] Radix Notoginseng total arasaponins 80g Radix Salviae Miltiorrhizae total phenolic acids 20g calcium sulfate 112g
Microcrystalline Cellulose 37g micropowder silica gel 2.3g magnesium stearate 1.1g
[method for making] got former, adjuvant and crossed 100 mesh sieves respectively; Get Radix Notoginseng total arasaponins, Radix Salviae Miltiorrhizae total phenolic acids, calcium sulfate, microcrystalline Cellulose, mixing in right amount as binding agent system soft material, is crossed 20 mesh sieve system granules with 60% ethanol; 60 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of micropowder silica gel and magnesium stearate; Mixing, tabletting is processed 1000, promptly gets.
Embodiment 3
[prescription] Radix Salviae Miltiorrhizae total phenolic acids 20g Radix Notoginseng total arasaponins 80g calcium sulfate 200g
Microcrystalline Cellulose 66g micropowder silica gel 4g magnesium stearate 2g
[method for making] got former, adjuvant and crossed 100 mesh sieves respectively; Get Radix Salviae Miltiorrhizae total phenolic acids, Radix Notoginseng total arasaponins, calcium sulfate, microcrystalline Cellulose, mixing in right amount as binding agent system soft material, is crossed 20 mesh sieve system granules with 60% ethanol; 60 ℃ of dryings are taken out, and cross 30 mesh sieve granulate, add an amount of micropowder silica gel and magnesium stearate; Mixing, tabletting is processed 1000, promptly gets.
Embodiment 4
Capsule
Get Radix Salviae Miltiorrhizae total phenolic acids 90g Radix Notoginseng total arasaponins 10g, add appropriate amount of starch, adjuvants such as magnesium stearate are granulated, granulate, and the capsule of packing into No. 1 promptly gets.
Embodiment 5
Oral liquid
Get Radix Salviae Miltiorrhizae total phenolic acids 70g Radix Notoginseng total arasaponins 20g, add an amount of sucrose, antiseptic adds water to 1000ml, is distributed into one of 10ml, promptly gets oral liquid.
Embodiment 6
Granule
Get Radix Salviae Miltiorrhizae total phenolic acids 10g Radix Notoginseng total arasaponins 70g, add an amount of dextrin, steviosin, dry granulation, granulate, packing promptly gets.
Embodiment 7
Injection
Radix Salviae Miltiorrhizae total phenolic acids 30g Radix Notoginseng total arasaponins 75g is dissolved in water, and sodium chloride, ethylparaben add the hot water dissolving, mixing, adjust pH in addition.Water for injection is diluted to 1000ml, filters with hollow-fibre membrane, and fill, sterilization promptly gets.
Claims (10)
1. the application of the compositions of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins in a kind of medicine that suppresses mast cell degranulation of preparation treatment.
2. the application of claim 1 is characterized in that, the compatibility of said Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins with weight ratio 2: 8-8: 2 mixed.
3. the application of claim 1 is characterized in that, said compositions is used for preparing the application of the microcirculation disturbance that the treatment mast cell degranulation causes.
4. the application of claim 1 is characterized in that, the compatibility of said Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is that Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins are with 8: 2 mixed of weight ratio.
5. the application of claim 1 is characterized in that, the compatibility of said Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins is that Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins are with 2: 8 mixed of weight ratio.
6. the application of claim 1 is characterized in that, the weight compatibility ratio of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins be 2: 8 preparatory administration to ischemia-reperfusion after between mesentery the matter mast cell degranulation inhibitory action is arranged.
7. the application of claim 1, said application is to pollinosis, dermatosis, asthma, the application of the microcirculation disturbance that diarrhoea causes.
8. the application of claim 1 is characterized in that, said pharmaceutical composition as active constituents of medicine, contains the medicine acceptable carrier with the compatibility of Radix Salviae Miltiorrhizae total phenolic acids and Radix Notoginseng total arasaponins simultaneously.
9. the application of claim 8 is characterized in that, said pharmaceutical composition is as any pharmaceutically useful dosage form.
10. the application of claim 9; It is characterized in that said dosage form is selected from: tablet, capsule, oral liquid, suck agent, granule, pill, powder, unguentum, sublimed preparation, suspensoid, solution, injection, suppository, cream, spray, drop or patch.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810052995A CN101574391B (en) | 2008-05-05 | 2008-05-05 | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside |
| PCT/CN2009/071632 WO2009135433A1 (en) | 2008-05-05 | 2009-05-04 | Use of total salvianolic acid, panax notoginsenosides and combination thereof in treating septicemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810052995A CN101574391B (en) | 2008-05-05 | 2008-05-05 | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101574391A CN101574391A (en) | 2009-11-11 |
| CN101574391B true CN101574391B (en) | 2012-08-29 |
Family
ID=41264441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810052995A Active CN101574391B (en) | 2008-05-05 | 2008-05-05 | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101574391B (en) |
| WO (1) | WO2009135433A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048818A (en) * | 2009-11-05 | 2011-05-11 | 天津天士力制药股份有限公司 | Total salvianolic acid, panax notoginseng saponins, and compatibility thereof in prevention and treatment of diseases caused by microcirculatory disturbance |
| CN102100739B (en) * | 2009-12-17 | 2013-12-25 | 天士力制药集团股份有限公司 | Traditional Chinese medicine composition containing salvianic acid A and pseudoginseng root saponin R1 and application thereof |
| CN101912441A (en) * | 2010-08-18 | 2010-12-15 | 江西本草天工科技有限责任公司 | Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101006984B (en) * | 2007-02-01 | 2010-05-19 | 北京本草天源药物研究院 | An injection preparation containing salvianolic acid A and extract of panax natoginseng, and its preparation method and application |
| CN101327235B (en) * | 2007-06-21 | 2011-08-10 | 天津天士力制药股份有限公司 | Use of pseudo-ginseng saponins for treating septicemia |
| CN101327249B (en) * | 2007-06-21 | 2012-07-18 | 天津天士力制药股份有限公司 | Use of hydroxyphenyl lactic acid in preparing medicine for treating septicemia |
-
2008
- 2008-05-05 CN CN200810052995A patent/CN101574391B/en active Active
-
2009
- 2009-05-04 WO PCT/CN2009/071632 patent/WO2009135433A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN101574391A (en) | 2009-11-11 |
| WO2009135433A1 (en) | 2009-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104224811B (en) | A kind of Radix Salviae Miltiorrhizae drug and preparation method thereof | |
| CN103006838B (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN101574391B (en) | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside | |
| DK2514418T3 (en) | TRADITIONAL CHINESE PHARMACEUTICAL INCLUDING DANSHEN EXTRACTS AND SANQI EXTRACTS AND USE THEREOF | |
| CN101327235B (en) | Use of pseudo-ginseng saponins for treating septicemia | |
| CN101574357A (en) | Prevention and treatment of diseases induced by microcirculation disturbance with panax notoginseng saponins R1 | |
| CN101574383A (en) | Prevention and treatment of diseases induced by microcirculation disturbance with panax notoginoside | |
| CN104435045A (en) | Traditional Chinese medicine composition for treating stroke and sequela thereof and preparation method thereof | |
| CN101721467B (en) | Method for preparing total salvianolic acid | |
| CN101156882A (en) | Preparation method of pseudo-ginseng protopanoxadiol saponin and its uasage | |
| CN111714539B (en) | Liver-protecting composition and preparation method and application thereof | |
| CN101574392B (en) | Prevention and treatment of diseases induced by microcirculation disturbance with total salvianolic acid | |
| CN101530465B (en) | Total salvianolic acid and Panax notoginsenosides and application of mixture thereof in treatment of septicemia | |
| CN1732964A (en) | Pharmaceutical composition, its preparation process and usage | |
| CN104435105B (en) | One kind is by Radix Astragali, Radix Salviae Miltiorrhizae, Radix Notoginseng, the pharmaceutical composition of dalbergia wood preparation | |
| CN1919251B (en) | Traditional Chinese medicine composition for treating cardiac vascular disease | |
| CN101574424B (en) | Application of medicine combination in preparing medicament with function of protecting pancreatic island | |
| CN101574454B (en) | Restoration traditional Chinese medicine | |
| CN101190253B (en) | Medicinal composition containing mongolian snakegourd and notoginseng | |
| CN102048818A (en) | Total salvianolic acid, panax notoginseng saponins, and compatibility thereof in prevention and treatment of diseases caused by microcirculatory disturbance | |
| CN102048720A (en) | Tanshinol and notoginsenoside R1, as well as application of compatibility thereof for preventing and treating diseases caused by microcirculation disturbance | |
| CN101574358A (en) | Application of ginsenoside Rb1 in prevention and treatment of diseases induced by microcirculation disturbance | |
| CN100371002C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN117919331A (en) | Application of traditional Chinese medicine composition in preparation of health food or medicine for treating chronic congestive heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address |